Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion

American Journal of Ophthalmology

Volumn 157, Issue 1, 2014, Pages

  Tan, Mei Hong ^a,b   McAllister, Ian L ^a,b   Gillies, Mark E ^c   Verma, Nitin ^d   Banerjee, Gayatri ^e   Smithies, Lynne A ^a   Wong, Wan Ling ^f   Wong, Tien Y ^f,g  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e National University of Singapore ^*

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ANEURYSM; ARTICLE; BEST CORRECTED VISUAL ACUITY; BLADDER DYSFUNCTION; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CHEST INFECTION; CLINICAL ARTICLE; COLON CARCINOMA; COMPARATIVE EFFECTIVENESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA DISEASE; DEATH; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIPHORA; EYE DISCHARGE; EYE IRRITATION; EYE PAIN; EYE REDNESS; EYELID EDEMA; FALLING; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRID LASER; HEADACHE; HEALTH CARE QUALITY; HEART PALPITATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LASER COAGULATION; LOW LEVEL LASER THERAPY; MACULAR THICKNESS; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NECROTIZING FASCIITIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OCULAR PRURITUS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RASH; RETINA FOVEA; RETINA MACULA EDEMA; SCORING SYSTEM; TREATMENT OUTCOME; URETHRA DISEASE; URINARY TRACT INFECTION; VERY ELDERLY; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS FLOATERS;

EID: 84890448796     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.08.013     Document Type: Article

References (24)

1. P. Mitchell, W. Smith, and A. Chang Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study Arch Ophthalmol 114 10 1996 1243 1247
2. R. Klein, B.E. Klein, S.E. Moss, and S.M. Meuer The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study Trans Am Ophthalmol Soc 98 2000 133 141
3. S. Rogers, R.L. McIntosh, and N. Cheung The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia Ophthalmology 117 2 2010 313 319
4. R. Klein, S.E. Moss, S.M. Meuer, and B.E. Klein The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study Arch Ophthalmol 126 4 2008 513 518
5. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group Am J Ophthalmol 98 3 1984 271 282
6. S.L. Rogers, R.L. McIntosh, and L. Lim Natural history of branch retinal vein occlusion: an evidence-based systematic review Ophthalmology 117 6 2010 1094 1101
7. T.Y. Wong, and I.U. Scott Clinical practice. Retinal-vein occlusion N Engl J Med 363 22 2010 2135 2144
8. R.L. McIntosh, Q. Mohamed, S.M. Saw, and T.Y. Wong Interventions for branch retinal vein occlusion: an evidence-based systematic review Ophthalmology 114 5 2007 835 854
9. I.U. Scott, M.S. Ip, and P.C. VanVeldhuisen A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6 Arch Ophthalmol 127 9 2009 1115 1128
10. J.A. Haller, F. Bandello, and R.J. Belfort Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion Ophthalmology 117 6 2010 1134 1146
11. J. Pe'er, R. Folberg, and A. Itin Vascular endothelial growth factor upregulation in human central retinal vein occlusion Ophthalmology 105 3 1998 412 416
12. P.A. Campochiaro, J.S. Heier, and L. Feiner Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 6 2010 1102 1112
13. D.M. Brown, P.A. Campochiaro, and R.B. Bhisitkul Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 8 2011 1594 1602
14. S.J. Pieris, and D.W. Hill Collateral vessels in branch retinal vein occlusion Trans Ophthalmol Soc U K 102 Pt 1 1982 178 181
15. J. Ben-Nun Capillary blood flow in acute branch retinal vein occlusion Retina 21 5 2001 509 512
16. O. Genevois, M. Paques, and M. Simonutti Microvascular remodeling after occlusion-recanalization of a branch retinal vein in rats Invest Ophthalmol Vis Sci 45 2 2004 594 600
17. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group Arch Ophthalmol 115 4 1997 486 491
18. J. Rehak, L. Dusek, and O. Chrapek Initial visual acuity is an important prognostic factor in patients with branch retinal vein occlusion Ophthalmic Res 45 4 2011 204 209
19. M. Funk, K. Kriechbaum, and F. Prager Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab Invest Ophthalmol Vis Sci 50 3 2009 1025 1032
20. M. Funk, D. Karl, and M. Georgopoulos Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab Ophthalmology 116 12 2009 2393 2399
21. M.W. Stewart, P.J. Rosenfeld, and F.M. Penha Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) Retina 32 3 2012 434 457
22. A.E. Hoeh, T. Ach, K.B. Schaal, A.F. Scheuerle, and S. Dithmar Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion Graefes Arch Clin Exp Ophthalmol 247 12 2009 1635 1641
23. P.A. Campochiaro, G. Hafiz, and R. Channa Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes Ophthalmology 117 12 2010 2387 2394
24. J.S. Heier, P.A. Campochiaro, and L. Yau Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 4 2012 802 809